Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

In the Research Article “Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis” by Langer-Gould et al.,1 in the Methods section, item 7 of the eligibility criteria (third sentence under Specifications of the Target Trial) should be “… (7) not converting to SPMS within the first 12 months since the first RTX dose.”